Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Long Term DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Total Non-Current Liabilities: 2022-2024

Historic Total Non-Current Liabilities for Abivax (ABVX) over the last 3 years, with Dec 2024 value amounting to $75.5 million.

  • Abivax's Total Non-Current Liabilities fell 25.17% to $62.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $62.9 million, marking a year-over-year decrease of 25.17%. This contributed to the annual value of $75.5 million for FY2024, which is 73.86% up from last year.
  • Latest data reveals that Abivax reported Total Non-Current Liabilities of $75.5 million as of FY2024, which was up 73.86% from $43.4 million recorded in FY2023.
  • In the past 5 years, Abivax's Total Non-Current Liabilities ranged from a high of $75.5 million in FY2024 and a low of $17.8 million during FY2022.
  • For the 3-year period, Abivax's Total Non-Current Liabilities averaged around $45.6 million, with its median value being $43.4 million (2023).
  • Data for Abivax's Total Non-Current Liabilities shows a peak YoY surged of 143.90% (in 2023) over the last 5 years.
  • Abivax's Total Non-Current Liabilities (Yearly) stood at $17.8 million in 2022, then spiked by 143.90% to $43.4 million in 2023, then spiked by 73.86% to $75.5 million in 2024.